

# Margaret M Centenera

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3451667/margaret-m-centenera-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

1,582  
citations

18  
h-index

39  
g-index

41  
ext. papers

1,950  
ext. citations

7.1  
avg, IF

4.2  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 36 | Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 6131-40  | 10.1 | 277       |
| 35 | Dual roles of PARP-1 promote cancer growth and progression. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1134-49  | 24.4 | 260       |
| 34 | Maximizing the Therapeutic Potential of HSP90 Inhibitors. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 1445-51  | 6.6  | 123       |
| 33 | Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. <i>Nature Communications</i> , <b>2013</b> , 4, 1923  | 17.4 | 106       |
| 32 | The contribution of different androgen receptor domains to receptor dimerization and signaling. <i>Molecular Endocrinology</i> , <b>2008</b> , 22, 2373-82  |      | 103       |
| 31 | Ex vivo culture of human prostate tissue and drug development. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 483-5  | 7.5  | 96        |
| 30 | Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3562-70   | 12.9 | 85        |
| 29 | A patient-derived explant (PDE) model of hormone-dependent cancer. <i>Molecular Oncology</i> , <b>2018</b> , 12, 1608-1622  | 7.9  | 54        |
| 28 | Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, R219-27  | 5.7  | 54        |
| 27 | Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. <i>Oncotarget</i> , <b>2013</b> , 4, 691-704                     | 3.3  | 43        |
| 26 | GSTP1 DNA methylation and expression status is indicative of 5-aza-2'deoxyctidine efficacy in human prostate cancer cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e25634  | 3.7  | 41        |
| 25 | Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 949-962   | 6.6  | 41        |
| 24 | Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. <i>ELife</i> , <b>2020</b> , 9,  | 8.9  | 31        |
| 23 | Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 308-317  | 4.2  | 28        |
| 22 | Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. <i>European Urology Oncology</i> , <b>2018</b> , 1, 325-337   | 6.7  | 23        |
| 21 | Hsp90: still a viable target in prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2013</b> , 1835, 211-8  | 11.2 | 23        |
| 20 | The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2689-2700 | 6.1  | 22        |

|    |   |      |    |
|----|---|------|----|
| 19 | Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. <i>Molecular and Cellular Proteomics</i> , <b>2018</b> , 17, 1470-1486   | 7.6  | 19 |
| 18 | Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, 805-18   | 5.7  | 18 |
| 17 | A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response. <i>Prostate</i> , <b>2016</b> , 76, 1546-1559   | 4.2  | 18 |
| 16 | New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2018</b> , 8,   | 5.4  | 17 |
| 15 | Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. <i>Molecular Endocrinology</i> , <b>2006</b> , 20, 1009-24   |      | 16 |
| 14 | ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 1704-1718  | 10.1 | 16 |
| 13 | Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. <i>Scientific Reports</i> , <b>2018</b> , 8, 2090   | 4.9  | 15 |
| 12 | Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry. <i>Scientific Reports</i> , <b>2019</b> , 9, 15008   | 4.9  | 10 |
| 11 | Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. <i>Cancer Research</i> , <b>2021</b> , 81, 4981-4993  | 10.1 | 8  |
| 10 | IBI mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. <i>BMC Cancer</i> , <b>2016</b> , 16, 141  | 4.8  | 6  |
| 9  | A feedback loop between the androgen receptor and 6-phosphogluconate dehydrogenase (6PGD) drives prostate cancer growth. <i>ELife</i> , <b>2021</b> , 10,   | 8.9  | 6  |
| 8  | Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). <i>BMJ Open</i> , <b>2020</b> , 10, e033667 | 3    | 5  |
| 7  | Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 860-870  | 6.2  | 5  |
| 6  | Finding the place of histone deacetylase inhibitors in prostate cancer therapy. <i>Expert Review of Clinical Pharmacology</i> , <b>2009</b> , 2, 619-30   | 3.8  | 4  |
| 5  | Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 1500-1511   | 6.6  | 3  |
| 4  | Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition  |      | 2  |
| 3  | Insights from AR Gene Mutations <b>2009</b> , 207-240   |      | 1  |
| 2  | Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. <i>Nuclear Medicine and Biology</i> , <b>2021</b> , 93, 37-45   | 2.1  | 0  |

1 Androgens and the androgen receptor (AR)378-391